KemPharm to Present at Upcoming Investor Conferences
March 05 2019 - 7:30AM
KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company
focused on the discovery and development of proprietary prodrugs,
today announced that management will present at several investor
conferences during March 2019.
Details of KemPharm's presentations are as follows:
|
Event: |
Cowen and
Company 39th Annual Health Care Conference |
|
Date: |
Tuesday, March 12,
2019 |
|
Time: |
11:20 AM (ET) |
|
Location: |
The Boston Marriott
Copley Place, Boston, MA |
|
Room: |
St. Botolph Room, 2nd
Floor |
|
|
|
|
Event: |
31st Annual
ROTH Conference |
|
Date: |
Monday, March 18,
2019 |
|
Time: |
10:30 AM (PT) |
|
Location: |
The Ritz Carlton, Dana
Point, CA |
|
Room: |
Pink – Salon 5 |
|
|
|
|
Event: |
Oppenheimer
& Co. 29th Annual Healthcare Conference |
|
Date: |
Tuesday, March 19,
2019 |
|
Time: |
9:10 AM (ET) |
|
Location: |
The Westin New York
Grand Central, New York, NY |
|
Room: |
Track 61 |
All presentation webcasts will be available on the Investor
Relations section of the KemPharm website at
http://investors.kempharm.com/ following delivery at the respective
conferences.
About KemPharm:
KemPharm is a specialty pharmaceutical company
focused on the discovery and development of proprietary prodrugs to
treat serious medical conditions through its proprietary
LAT™ (Ligand Activated Therapy) technology. KemPharm
utilizes its proprietary LAT technology to generate improved
prodrug versions of FDA-approved drugs as well as to generate
prodrug versions of existing compounds that may have applications
for new disease indications. KemPharm’s prodrug product candidate
pipeline is focused on the high need areas of attention deficit
hyperactivity disorder, or ADHD, and stimulant use disorder.
KemPharm’s co-lead clinical development candidates for the
treatment of ADHD, KP415 and KP484, are both based on a prodrug of
d-methylphenidate, but have differing duration/effect profiles. In
addition, KemPharm has received FDA approval for APADAZ®, an
immediate-release combination product containing benzhydrocodone, a
prodrug of hydrocodone, and acetaminophen. For more information on
KemPharm and its pipeline of prodrug product candidates visit
www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook
and YouTube.
Investor/Media Contacts: |
Jason
Rando / Joshua Drumm, Ph.D.Tiberend Strategic Advisors,
Inc.212-375-2665 / 2664jrando@tiberend.comjdrumm@tiberend.com |
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Sep 2023 to Sep 2024